Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL11024520 | 0.83 | TAAR1 (0.59) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL11973522 | 0.83 | MEN1 (0.48) | TAAR1ALOX5ESR2 | |
| SCHEMBL31491189 | 0.83 | TAAR1 (0.71) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL16394285 | 0.83 | TAAR1 (0.71) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL31222672 | 0.83 | ALOX5 (0.65) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL817554 | 0.83 | ALOX5 (0.65) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL29788033 | 0.80 | TAAR1 (0.61) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL20669453 | 0.80 | TAAR1 (0.68) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL170231 | 0.80 | TAAR1 (0.61) | TAAR1ALOX5MAOBESR2PGR | |
| Hydrochloric Acid SCHEMBL31070804 | 0.80 | ALOX5 (0.62) | TAAR1ALOX5MAOBESR2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396465-A | Novel oxazole derivative for preventing or treating allergic diseases and pharmaceutical composition containing the same | 阿斯克里斯有限公司 | 2024-01-12 | — | — | CN | claimed |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-15 | — | — | US | claimed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | claimed |
| EP-3116851-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | Salk Institute for Biological Studies (US) | 2017-01-18 | — | — | EP | claimed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| WO-2015138969-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | claimed |
| EP-1212300-B1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-12 | — | — | US | claimed |
| US-6469029-B1 | INHIBITORS OF THROMBIN PRODUCTION VIA FACTOR XA INHIBITION; COUPLED TO MEDICAL DEVICES, SUCH AS STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-22 | — | — | US | claimed |
| CN-1373755-A | Azacycloalkanone serine protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-10-09 | — | — | CN | claimed |
| EP-1212300-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| EP-0821665-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 2001-10-04 | — | — | EP | claimed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-5831115-A | CYCLOBUTANECARBOXAMIDES | ABBOTT LABORATORIES (US) | 1998-11-03 | — | — | US | claimed |
| EP-0821665-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1998-02-04 | — | — | EP | claimed |
| WO-1996033159-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | LIPA, MGLL, PNLIP | TAAR1 2147/4885ALOX5 93/4885MAOB 437/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | TAAR1 2650/4885ALOX5 118/4885MAOB 1190/4885 |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | TAAR1 2650/4885ALOX5 118/4885MAOB 1190/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | TAAR1 2650/4885ALOX5 118/4885MAOB 1190/4885 |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | CTRL, SERPINE1, SERPINB1 | TAAR1 2282/4885ALOX5 722/4885MAOB 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.